Accurate reporting of adherence to inhaled therapies in adults with cystic fibrosis: methods to calculate "normative adherence"

被引：17

作者：

Hoo, Zhe Hui ^{[1
,2
]}

Curley, Rachael ^{[1
,2
]}

Campbell, Michael J. ^{[1
]}

Walters, Stephen J. ^{[1
]}

Hind, Daniel ^{[3
]}

Wildman, Martin J. ^{[1
,2
]}

机构：

[1] Univ Sheffield, Sch Hlth & Related Res ScHARR, Sheffield, S Yorkshire, England

[2] No Gen Hosp, Sheffield Adult Cyst Fibrosis Ctr, Sheffield S5 7AU, S Yorkshire, England

[3] Univ Sheffield, Sheffield Clin Trials Res Unit, Sheffield, S Yorkshire, England

来源：

PATIENT PREFERENCE AND ADHERENCE | 2016年 / 10卷

基金：

美国国家卫生研究院;

关键词：

cystic fibrosis; medication adherence; nebulizers and vaporizers; epidemiologic methods; PSEUDOMONAS-AERUGINOSA INFECTION; LONG-TERM SURVIVORS; PULMONARY EXACERBATION; MEDICATION ADHERENCE; TREATMENT COMPLEXITY; AZTREONAM LYSINE; TREATMENT BURDEN; DORNASE ALPHA; FEV1; DECLINE; RISK-FACTORS;

D O I：

10.2147/PPA.S105530

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Background: Preventative inhaled treatments in cystic fibrosis will only be effective in maintaining lung health if used appropriately. An accurate adherence index should therefore reflect treatment effectiveness, but the standard method of reporting adherence, that is, as a percentage of the agreed regimen between clinicians and people with cystic fibrosis, does not account for the appropriateness of the treatment regimen. We describe two different indices of inhaled therapy adherence for adults with cystic fibrosis which take into account effectiveness, that is, "simple" and "sophisticated" normative adherence. Methods to calculate normative adherence: Denominator adjustment involves fixing a minimum appropriate value based on the recommended therapy given a person's characteristics. For simple normative adherence, the denominator is determined by the person's Pseudomonas status. For sophisticated normative adherence, the denominator is determined by the person's Pseudomonas status and history of pulmonary exacerbations over the previous year. Numerator adjustment involves capping the daily maximum inhaled therapy use at 100% so that medication overuse does not artificially inflate the adherence level. Three illustrative cases: Case A is an example of inhaled therapy under prescription based on Pseudomonas status resulting in lower simple normative adherence compared to unadjusted adherence. Case B is an example of inhaled therapy under-prescription based on previous exacerbation history resulting in lower sophisticated normative adherence compared to unadjusted adherence and simple normative adherence. Case C is an example of nebulizer overuse exaggerating the magnitude of unadjusted adherence. Conclusion: Different methods of reporting adherence can result in different magnitudes of adherence. We have proposed two methods of standardizing the calculation of adherence which should better reflect treatment effectiveness. The value of these indices can be tested empirically in clinical trials in which there is careful definition of treatment regimens related to key patient characteristics, alongside accurate measurement of health outcomes.

引用

页码：887 / +

页数：14

共 88 条

[1] Adherence to Ivacaftor is suboptimal [J].

Abbott, Janice ;

Bilton, Diana .

JOURNAL OF CYSTIC FIBROSIS, 2015, 14 (05) :547-548

[2] Effective strategies for managing new Pseudomonas cultures in adults with cystic fibrosis [J].

Ali, Haider ;

Orchard, Christopher ;

Mariveles, Myril ;

Scott, Sandra ;

Alshafi, Khalid ;

Bilton, Diana ;

Simmonds, Nicholas .

EUROPEAN RESPIRATORY JOURNAL, 2015, 46 (03) :862-865

[3] Repeated nebulisation of non-viral CFTR gene therapy in patients with cystic fibrosis: a randomised, double-blind, placebo-controlled, phase 2b trial [J].

Alton, Eric W. F. W. ;

Armstrong, David K. ;

Ashby, Deborah ;

Bayfield, Katie J. ;

Bilton, Diana ;

Bloomfield, Emily V. ;

Boyd, A. Christopher ;

Brand, June ;

Buchan, Ruaridh ;

Calcedo, Roberto ;

Carvelli, Paula ;

Chan, Mario ;

Cheng, Seng H. ;

Collie, D. David S. ;

Cunningham, Steve ;

Davidson, Heather E. ;

Davies, Gwyneth ;

Davies, Jane C. ;

Davies, Lee A. ;

Dewar, Maria H. ;

Doherty, Ann ;

Donovan, Jackie ;

Dwyer, Natalie S. ;

Elgmati, Hala I. ;

Featherstone, Rosanna F. ;

Gavino, Jemyr ;

Gea-Sorli, Sabrina ;

Geddes, Duncan M. ;

Gibson, James S. R. ;

Gill, Deborah R. ;

Greening, Andrew P. ;

Griesenbach, Uta ;

Hansell, David M. ;

Harman, Katharine ;

Higgins, Tracy E. ;

Hodges, Samantha L. ;

Hyde, Stephen C. ;

Hyndman, Laura ;

Innes, J. Alastair ;

Jacob, Joseph ;

Jones, Nancy ;

Keogh, Brian F. ;

Limberis, Maria P. ;

Lloyd-Evans, Paul ;

Maclean, Alan W. ;

Manvell, Michelle C. ;

McCormick, Dominique ;

McGovern, Michael ;

McLachlan, Gerry ;

Meng, Cuixiang .

LANCET RESPIRATORY MEDICINE, 2015, 3 (09) :684-691

[4] Inhaled aztreonam lysine vs. inhaled tobramycin in cystic fibrosis: A comparative efficacy trial [J].

Assael, Baroukh M. ;

Pressler, Tacjana ;

Bilton, Diana ;

Fayon, Michael ;

Fischer, Rainald ;

Chiron, Raphael ;

LaRosa, Mario ;

Knoop, Christiane ;

McElvaney, Noel ;

Lewis, Sandra A. ;

Bresnik, Mark ;

Montgomery, A. Bruce ;

Oermann, Christopher M. .

JOURNAL OF CYSTIC FIBROSIS, 2013, 12 (02) :130-140

[5] The changing face of the exocrine pancreas in cystic fibrosis: the correlation between pancreatic status, pancreatitis and cystic fibrosis genotype [J].

Augarten, Arie ;

Ben Tov, Amir ;

Madgar, Igal ;

Barak, Asher ;

Akons, Hanna ;

Laufer, Joseph ;

Efrati, Ori ;

Aviram, Micha ;

Bentur, Lea ;

Blau, Hannah ;

Paret, Gideon ;

Wilschanski, Michael ;

Kerem, Bat-Sheva ;

Yahav, Yaakov .

EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2008, 20 (03) :164-168

[6]

Ballmann Manfred, 2002, J Cyst Fibros, V1, P35, DOI 10.1016/S1569-1993(01)00009-1

[7] Predictors of pulmonary exacerbations in patients with cystic fibrosis infected with multi-resistant bacteria [J].

Block, J. K. ;

Vandemheen, K. L. ;

Tullis, E. ;

Fergusson, D. ;

Doucette, S. ;

Haase, D. ;

Berthiaume, Y. ;

Brown, N. ;

Wilcox, P. ;

Bye, P. ;

Bell, S. ;

Noseworthy, M. ;

Pedder, L. ;

Freitag, A. ;

Paterson, N. ;

Aaron, S. D. .

THORAX, 2006, 61 (11) :969-974

[8] Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice [J].

Castellani, C. ;

Cuppens, H. ;

Macek, M., Jr. ;

Cassinian, J. J. ;

Kerern, E. ;

Durie, P. ;

Tullis, E. ;

Assael, B. M. ;

Bombieri, C. ;

Brown, A. ;

Casals, T. ;

Claustres, M. ;

Cutting, G. R. ;

Dequeker, E. ;

Dodge, J. ;

Doull, I. ;

Farrell, P. ;

Ferec, C. ;

Girodon, E. ;

Johannesson, M. ;

Kerem, B. ;

Knowles, M. ;

Munck, A. ;

Pignatti, P. F. ;

Radojkovic, D. ;

Rizzotti, P. ;

Schwarz, M. ;

Stuhnnann, M. ;

Tzetis, M. ;

Zielenski, J. ;

Elborn, J. S. .

JOURNAL OF CYSTIC FIBROSIS, 2008, 7 (03) :179-196

[9] Accurate Assessment of Adherence Self-Report and Clinician Report vs Electronic Monitoring of Nebulizers [J].

Daniels, Tracey ;

Goodacre, Lynne ;

Sutton, Chris ;

Pollard, Kim ;

Conway, Steven ;

Peckham, Daniel .

CHEST, 2011, 140 (02) :425-432

[10] Cystic fibrosis [J].

Davies, Jane C. ;

Alton, Eric W. F. W. ;

Bush, Andrew .

BMJ-BRITISH MEDICAL JOURNAL, 2007, 335 (7632) :1255-1259

← 1 2 3 4 5 6 7 8 9 →